METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA
The present disclosure relates to methods of treating organic acidemias with 2.2-dimethylbutyric acid or pharmaceutically acceptable salt thereof.
1 - 51 . (canceled)
52 . A method of treating an organic acidemia in a subject in need thereof, comprising:
administering about 0.5 mg/kg to about 30 mg/kg of 2,2-dimethylbutyric acid, or an equivalent amount of a pharmaceutically acceptable salt or ester thereof, to the subject,
thereby treating the organic acidemia.
53 . A method of treating propionic acidemia or methylmalonic acidemia in a subject in need thereof, comprising:
orally administering about 1 mg/kg to about 30 mg/kg of sodium 2,2-dimethylbutanoate, or an equivalent amount of 2,2-dimethylbutyric acid or a different pharmaceutically acceptable salt or ester thereof, to the subject,
thereby treating propionic acidemia or methylmalonic acidemia.
54 . The method of claim 53 , wherein the organic acidemia is propionic acidemia.
55 . The method of claim 53 , wherein the organic acidemia is methylmalonic acidemia.
56 . The method of claim 53 , wherein about 1 mg/kg, about 3 mg/kg, about 6 mg/kg, 9 mg/kg, about 10 mg/kg, about 15 mg/kg, about 18 mg/kg, or about 30 mg/kg of sodium 2,2-dimethylbutyrate is administered to the subject per day.
57 . The method of claim 56 , wherein sodium 2,2-dimethylbutyrate is formulated as an oral solution.
58 . The method of claim 57 , wherein the oral solution comprises from about 5 mg/ml to about 75 mg/mL of sodium 2,2-dimethylbutyrate.
59 . The method of claim 57 , wherein the oral solution comprises from about 10 mg/mL to about 70 mg/mL of sodium 2,2-dimethylbutyrate.
60 . The method of claim 53 , wherein the treating comprises reducing propionic acid, 3-hydroxypropionic acid, methylcitrate, glycine, propionylcarnitine, or combinations thereof in the subject compared to baseline or a control.
61 . The method of claim 53 , wherein the treating comprises reducing 2-ketoisocaproate, isovaleryl-CoA, 3-methylcrotonyl-CoA, 3-methylglutaconyl-CoA, 3-OH-3-methylglutaryl-CoA, 2-keto-3-methylvalerate, 2-methylbutyryl-CoA, tiglyl-CoA, 2-methyl-3-OH-butyryl-CoA, 2-methyl-acetoacetyl-CoA, 2-ketoisovalerate, isobutyryl-CoA, methylacrylyl-CoA, 3-OH-isobutyryl-CoA, 3-OH-isobutyrate, methylmalonic semialdehyde, propionyl-CoA, or methylmalonyl-CoA, or combinations thereof, in the subject compared to baseline or a control.
62 . The method of claim 60 , wherein the at least one metabolite is reduced by an amount ranging from at least about 10% to about 100%.
63 . The method of claim 61 , wherein the at least one metabolite is reduced by an amount ranging from at least about 10% to about 100%.
64 . The method of claim 53 , wherein about 3 mg/kg of sodium 2,2-dimethylbutanoate is administered twice a day.
65 . The method of claim 53 , wherein about 9 mg/kg of sodium 2,2-dimethylbutanoate is administered twice a day.
66 . The method of claim 53 , wherein about 15 mg/kg of sodium 2,2-dimethylbutanoate is administered twice a day.
67 . The method of claim 53 , wherein the subject is 2 to 11 years old.
68 . The method of claim 53 , wherein the subject is 12 years old or older.
69 . The method of claim 53 , wherein the subject is 2 years old or younger.
70 . The method of claim 53 , wherein the total daily dose of sodium 2,2-dimethylbutanoate administered is about 6 mg/kg.
71 . The method of claim 53 , wherein the total daily dose of sodium 2,2-dimethylbutanoate administered is about 18 mg/kg.
72 . The method of claim 53 , wherein the total daily dose of sodium 2,2-dimethylbutanoate administered is about 30 mg/kg.
73 . The method of claim 53 , wherein the treating comprises reducing MCA levels, plasma MCA: citric acid ratio, plasma propionyl-carnitine to acetyl carnitine ratio, 3-OH propionate levels, propionyl-carnitine levels, ammonia (NH 3 ) levels, anion gap, carnitine levels, ketone levels, lactic acid levels, ketone urine levels, organic acid levels, acylglycines levels, QT corrected (QTc) intervals, a left ventricular ejection fraction, plasma and urinary metabolites, plasma fibroblast growth factor 21 (FGF-21) levels, or combinations thereof, in the subject compared to baseline or a control.
74 . The method of claim 53 , wherein the treating comprises reducing a frequency of metabolic decompensation events requiring an emergency room visit or hospitalization; a frequency of days in the hospital required for treatment/resolution of metabolic decompensations; and/or frequency of episodes and/or days requiring use of a home emergency treatment protocol for metabolic decompensations, in the subject compared to baseline or a control.
75 . The method of claim 53 , wherein the subject exhibits an increase in plasma sodium 2,2-dimethylbutyrate levels after administration.
76 . The method of claim 53 , wherein the treating comprises improving health-related quality of life (HrQoL) in the subject.
77 . The method of claim 76 , wherein the treating comprises decreasing a MetabQOL 1.0 score of the subject by 1, 2, 3, or 4.
78 . The method of claim 76 , wherein the treating decreases a PedsQL score of the subject by 1, 2, 3, or 4.
79 . The method of claim 76 , wherein the treating decreases Clinician-Reported Global Assessments of Severity and Change score of the subject by 1, 2, 3, 4, 5, or 6.